Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1181 | 2701 | 32.6 | 72% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | DEFERASIROX | Author keyword | 217 | 72% | 6% | 172 |
2 | IRON OVERLOAD | Author keyword | 206 | 33% | 19% | 509 |
3 | DEFERIPRONE | Author keyword | 116 | 56% | 5% | 142 |
4 | THALASSEMIA | Author keyword | 110 | 25% | 14% | 388 |
5 | IRON CHELATION THERAPY | Author keyword | 94 | 77% | 2% | 64 |
6 | THALASSEMIA MAJOR | Author keyword | 53 | 41% | 4% | 102 |
7 | DEFERIPRONE L1 | Author keyword | 51 | 79% | 1% | 33 |
8 | IRON CHELATION | Author keyword | 45 | 32% | 4% | 118 |
9 | DEFEROXAMINE DFO | Author keyword | 40 | 82% | 1% | 23 |
10 | EXJADE | Author keyword | 31 | 92% | 0% | 12 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | DEFERASIROX | 217 | 72% | 6% | 172 | Search DEFERASIROX | Search DEFERASIROX |
2 | IRON OVERLOAD | 206 | 33% | 19% | 509 | Search IRON+OVERLOAD | Search IRON+OVERLOAD |
3 | DEFERIPRONE | 116 | 56% | 5% | 142 | Search DEFERIPRONE | Search DEFERIPRONE |
4 | THALASSEMIA | 110 | 25% | 14% | 388 | Search THALASSEMIA | Search THALASSEMIA |
5 | IRON CHELATION THERAPY | 94 | 77% | 2% | 64 | Search IRON+CHELATION+THERAPY | Search IRON+CHELATION+THERAPY |
6 | THALASSEMIA MAJOR | 53 | 41% | 4% | 102 | Search THALASSEMIA+MAJOR | Search THALASSEMIA+MAJOR |
7 | DEFERIPRONE L1 | 51 | 79% | 1% | 33 | Search DEFERIPRONE+L1 | Search DEFERIPRONE+L1 |
8 | IRON CHELATION | 45 | 32% | 4% | 118 | Search IRON+CHELATION | Search IRON+CHELATION |
9 | DEFEROXAMINE DFO | 40 | 82% | 1% | 23 | Search DEFEROXAMINE+DFO | Search DEFEROXAMINE+DFO |
10 | EXJADE | 31 | 92% | 0% | 12 | Search EXJADE | Search EXJADE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MYOCARDIAL IRON | 467 | 90% | 8% | 204 |
2 | ICL670 | 219 | 83% | 5% | 123 |
3 | DEFEROXAMINE | 212 | 40% | 15% | 413 |
4 | DEFERIPRONE | 183 | 60% | 7% | 200 |
5 | BETA THALASSEMIA | 167 | 24% | 23% | 616 |
6 | CARDIAC IRON | 147 | 85% | 3% | 78 |
7 | T2 ASTERISK CARDIOVASCULAR MAGNETIC RESONANCE | 140 | 92% | 2% | 56 |
8 | CHELATION THERAPY | 136 | 46% | 8% | 222 |
9 | THALASSEMIA MAJOR | 134 | 40% | 10% | 262 |
10 | BETA THALASSEMIA MAJOR | 102 | 47% | 6% | 159 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis | 2015 | 2 | 39 | 74% |
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms | 2015 | 1 | 32 | 78% |
Labile iron in cells and body fluids: physiology, pathology, and pharmacology | 2014 | 11 | 57 | 47% |
Iron-chelating therapy and the treatment of thalassemia | 1997 | 562 | 184 | 61% |
Non-transferrin bound iron: A key role in iron overload and iron toxicity | 2012 | 83 | 114 | 33% |
Non-transfusion-dependent thalassemias | 2013 | 22 | 92 | 46% |
Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major | 2014 | 3 | 22 | 100% |
Iron chelation: an update | 2014 | 3 | 46 | 96% |
Beta-thalassemia | 2010 | 79 | 73 | 51% |
How I treat transfusional iron overload | 2012 | 18 | 114 | 92% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MICROCITEMIA | 30 | 79% | 0.7% | 19 |
2 | CA GRANDA FDN IRCCS | 26 | 87% | 0.5% | 13 |
3 | ANEMIE CONGENITE | 16 | 58% | 0.7% | 18 |
4 | THALASSEMIA | 15 | 21% | 2.3% | 61 |
5 | THALASSEMIA UNIT | 14 | 37% | 1.1% | 31 |
6 | CURA MICROCITEMIE | 14 | 100% | 0.3% | 7 |
7 | IRCCS CA GRANDA FDN MAGGIORE POLICLIN HOSP | 13 | 67% | 0.4% | 12 |
8 | THALASSAEMIA UNIT | 13 | 41% | 0.9% | 24 |
9 | UOS TALASSEMIA | 11 | 100% | 0.2% | 6 |
10 | OSPED REG MICROCITEMIE | 10 | 43% | 0.7% | 18 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000256835 | THALASSEMIA MAJOR//MOL DIAGNOST BIOPHARMACEUT//BETA THALASSEMIA MAJOR |
2 | 0.0000154406 | AHSP//ALPHA HEMOGLOBIN STABILIZING PROTEIN AHSP//ALPHA HEMOGLOBIN STABILIZING PROTEIN |
3 | 0.0000141361 | HYDROXYPYRIDINONES//3 HYDROXYPYRIDIN 4 ONE//HYDROXYPYRIDINONE |
4 | 0.0000136668 | INT TRANSPLANTAT THALASSEMIA SICKLE CELL AN//MEDITERRANEAN HEMATOL//TR IANTO MIDOLLO OSSEO MURAGLIA |
5 | 0.0000136186 | IRON METAB CHELAT PROGRAM//PYRIDOXAL ISONICOTINOYL HYDRAZONE//TRIAPINE |
6 | 0.0000084843 | CHIM COORDINAT BIOORGAN BIOINORGAN//DESFERRIOXAMINE NITROXIDE RADICAL//SOY LIPOXYGENASE |
7 | 0.0000076243 | IRON POISONING//IRON OVERDOSE//IRON INTOXICATION |
8 | 0.0000071971 | HEMOCHROMATOSIS//HFE//HFE GENE |
9 | 0.0000066179 | FERRIC SORBITOL CITRATE//FERRIC SORBITOL CITRATE FSC//NF KAPPA B EXPRESSION ACTIVATION |
10 | 0.0000051653 | EIJKMAN IMMUNOL INFECT DIS//MALATTIE METAB FEGATO//NUCLEAR MICROSCOPY |